ArticleClinical rheumatology2009

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Anthony Russell et al.PubMed ↗Publisher ↗

No numbers read from the abstract.